Cargando…

Recent advances in the medical treatment of breast cancer

Over the past few decades, the systemic therapy of breast cancer (early and advanced) has changed considerably. For the past 40–50 years, and since the discovery and further therapeutic use of tamoxifen, a selective estrogen receptor modulator, breast cancer treatment has become the model for the de...

Descripción completa

Detalles Bibliográficos
Autor principal: Vorobiof, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133691/
https://www.ncbi.nlm.nih.gov/pubmed/27990275
http://dx.doi.org/10.12688/f1000research.9619.1
_version_ 1782471317837053952
author Vorobiof, Daniel A.
author_facet Vorobiof, Daniel A.
author_sort Vorobiof, Daniel A.
collection PubMed
description Over the past few decades, the systemic therapy of breast cancer (early and advanced) has changed considerably. For the past 40–50 years, and since the discovery and further therapeutic use of tamoxifen, a selective estrogen receptor modulator, breast cancer treatment has become the model for the development and success of tailored medical treatment. Much still needs to be done in improving outcomes for all patients with breast cancer, and especially for those who have advanced breast cancer, a challenging area for medical oncologists. Ongoing international clinical trials are currently evaluating new therapeutic approaches and identifying specific biological subsets that could determine a patient’s ability to respond to particular chemotherapeutic drugs.
format Online
Article
Text
id pubmed-5133691
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-51336912016-12-16 Recent advances in the medical treatment of breast cancer Vorobiof, Daniel A. F1000Res Review Over the past few decades, the systemic therapy of breast cancer (early and advanced) has changed considerably. For the past 40–50 years, and since the discovery and further therapeutic use of tamoxifen, a selective estrogen receptor modulator, breast cancer treatment has become the model for the development and success of tailored medical treatment. Much still needs to be done in improving outcomes for all patients with breast cancer, and especially for those who have advanced breast cancer, a challenging area for medical oncologists. Ongoing international clinical trials are currently evaluating new therapeutic approaches and identifying specific biological subsets that could determine a patient’s ability to respond to particular chemotherapeutic drugs. F1000Research 2016-11-29 /pmc/articles/PMC5133691/ /pubmed/27990275 http://dx.doi.org/10.12688/f1000research.9619.1 Text en Copyright: © 2016 Vorobiof DA http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Vorobiof, Daniel A.
Recent advances in the medical treatment of breast cancer
title Recent advances in the medical treatment of breast cancer
title_full Recent advances in the medical treatment of breast cancer
title_fullStr Recent advances in the medical treatment of breast cancer
title_full_unstemmed Recent advances in the medical treatment of breast cancer
title_short Recent advances in the medical treatment of breast cancer
title_sort recent advances in the medical treatment of breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133691/
https://www.ncbi.nlm.nih.gov/pubmed/27990275
http://dx.doi.org/10.12688/f1000research.9619.1
work_keys_str_mv AT vorobiofdaniela recentadvancesinthemedicaltreatmentofbreastcancer